NON-SMALL-CELL LUNG CARCINOMA
Clinical trials for NON-SMALL-CELL LUNG CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new NON-SMALL-CELL LUNG CARCINOMA trials appear
Sign up with your email to follow new studies for NON-SMALL-CELL LUNG CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy shows promise in lung cancer battle
Disease control CompletedThis study tested a new immunotherapy drug, cemiplimab, against standard chemotherapy in 712 people with advanced non-small cell lung cancer that has a specific marker (PD-L1). The goal was to see if cemiplimab helps people live longer or keeps the cancer from growing longer than…
Matched conditions: NON-SMALL-CELL LUNG CARCINOMA
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Apr 29, 2026 02:39 UTC
-
New combo drug shows promise in advanced lung cancer battle
Disease control CompletedThis study tested a new drug combination (vibostolimab plus pembrolizumab) against pembrolizumab alone for people with a specific type of advanced lung cancer (PD-L1 positive metastatic non-small cell lung cancer). The goal was to see if the combination helps patients live longer…
Matched conditions: NON-SMALL-CELL LUNG CARCINOMA
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 29, 2026 02:39 UTC
-
Lung cancer study watches and waits: no new treatment, just observation
Knowledge-focused CompletedThis study looked at how doctors currently treat patients with a type of advanced lung cancer (non-small cell) that is located in the center of the chest and is not causing symptoms. The goal was to see whether doctors choose to give radiation right away or wait until symptoms ap…
Matched conditions: NON-SMALL-CELL LUNG CARCINOMA
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Apr 29, 2026 02:37 UTC